Abstract
Lipoprotein apheresis (LA) is currently (still) the most effective therapeutic approach to decrease the cardiovascular risk associated with high lipoprotein(a) [Lp(a)] concentrations. It is indicated in patients who developed cardiovascular events (CVEs), especially in those who show a progress of atherosclerosis despite a rather good compensation of all other risk factors [including LDL (low-density lipoprotein) cholesterol]. Several LA methods can be used; they all acutely reduce Lp(a) levels by more than 70%. The interval mean values are decreased by more than 50%, when compared with the Lp(a) concentration before the initiation of LA. Several observational and case control studies showed that an LA therapy leads to a lasting reduction of the incidence of CVEs by about 80–90% when taking into account the situation in the years before the start of LA. No randomized controlled study was performed, due to ethical concerns. In Germany, an LA registry exists. This review reports cases where the situation of arterial vessels was extremely critical; it shows certain limitations of the extracorporeal treatment. Finally, options to further improve the prognosis of patients (e.g., more LA sessions, adding PCSK9 inhibitors) and the future of LA therapy taking into consideration inhibitors of apolipoprotein(a) synthesis are discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- A:
-
Atorvastatin
- AIC:
-
Arteria iliaca communis
- Aorta-mes bypass:
-
Mesenteric artery bypass
- A. mes sup:
-
Arteria mesenterica superior
- ApoE:
-
Apolipoprotein E-polymorphism
- BMS:
-
Bare metal stent
- CAD:
-
Coronary artery disease
- CX:
-
Left circumflex coronary artery
- DEB:
-
Drug-eluting balloon
- DES:
-
Drug-eluting stent
- LAD:
-
Left anterior descending artery
- LCA:
-
Left coronary artery
- LMS:
-
Left main stem
- nk:
-
Not known
- MI:
-
Myocardial infarction
- PLA:
-
Posterolateral artery
- PTA:
-
Percutaneous transluminal angioplasty
- PTCA:
-
Percutaneous transluminal coronary angioplasty
- RCA:
-
Right coronary artery
- RDI:
-
Ramus diagonalis, diagonal branch 1
- R:
-
Rosuvastatin
- S:
-
Simvastatin
- TEA:
-
Thromboendarteriectomy
- Tr. coel:
-
Truncus coeliacus
References
Arai K, Orsoni A, Mallat Z, Tedgui A, Witztum JL, Bruckert E, et al. Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. J Lipid Res. 2012;53(8):1670–8. https://doi.org/10.1194/jlr.P027235.
Arnold M, Schweizer J, Nakas CT, Schutz V, Westphal LP, Inauen C, et al. Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study. Eur Heart J. 2021;42(22):2186–96. https://doi.org/10.1093/eurheartj/ehab081.
Bigazzi F, Sbrana F, Berretti D, Maria Grazia Z, Zambon S, Fabris A, et al. Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study. Transfus Apher Sci. 2018;57(5):661–4. https://doi.org/10.1016/j.transci.2018.07.015.
Boffa MB, Stranges S, Klar N, Moriarty PM, Watts GF, Koschinsky ML. Lipoprotein(a) and secondary prevention of atherothrombotic events: a critical appraisal. J Clin Lipidol. 2018;12(6):1358–66. https://doi.org/10.1016/j.jacl.2018.08.012.
Bundesministerium für Gesundheit. Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Richtlinie Methoden vertragsärztliche Versorgung: Apherese bei isolierter Lp(a)-Erhöhung. BAnz. 2008;138:3321.
Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 2018;3(7):619–27. https://doi.org/10.1001/jamacardio.2018.1470.
Cegla J, Neely RDG, France M, Ferns G, Byrne CD, Halcox J, et al. HEART UK consensus statement on lipoprotein(a): a call to action. Atherosclerosis. 2019;291:62–70. https://doi.org/10.1016/j.atherosclerosis.2019.10.011.
deVeber G, Kirkham F, Shannon K, Brandao L, Strater R, Kenet G, et al. Recurrent stroke: the role of thrombophilia in a large international pediatric stroke population. Haematologica. 2019;104(8):1676–81. https://doi.org/10.3324/haematol.2018.211433.
Dittrich-Riediger J, Schatz U, Hohenstein B, Julius U. Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden. Atheroscler Suppl. 2015;18:45–52. https://doi.org/10.1016/j.atherosclerosissup.2015.02.007.:45-52.
Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, et al. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: findings gathered from more than 36,000 treatments at one center in Germany. Atheroscler Suppl. 2015;18:154–62. https://doi.org/10.1016/j.atherosclerosissup.2015.02.013.
Hohenstein B, Julius U, Lansberg P, Jaeger B, Mellwig KP, Weiss N, et al. Rationale and design of MultiSELECt: a European Multicenter study on the effect of lipoprotein(a) elimination by lipoprotein apheresis on cardiovascular outcomes. Atheroscler Suppl. 2017;30:180–6. https://doi.org/10.1016/j.atherosclerosissup.2017.05.009.
Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6(3):229–39. https://doi.org/10.1038/ncpcardio1456.
Jiang X, Xu J, Hao X, Xue J, Li K, Jin A, et al. Elevated lipoprotein(a) and lipoprotein-associated phospholipase A2 are associated with unfavorable functional outcomes in patients with ischemic stroke. J Neuroinflamm. 2021;18(1):307. https://doi.org/10.1186/s12974-021-02359-w.
Julius U. Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection. Med Devices (Auckl). 2016;9:349–60. https://doi.org/10.2147/MDER.S98889.
Julius U. History of lipidology and lipoprotein apheresis. Atheroscler Suppl. 2017;30:1–8. https://doi.org/10.1016/j.atherosclerosissup.2017.05.034.
Julius U, Metzler W, Pietzsch J, Fassbender T, Klingel R. Intraindividual comparison of two extracorporeal LDL apheresis methods: lipid filtration and HELP. Int J Artif Organs. 2002;25(12):1180–8.
Julius U, Fischer S, Schatz U, Passauer J, Bornstein S. Why an apheresis center should offer more than one lipoprotein apheresis method. Ther Apher Dial. 2013;17(2):179–84. https://doi.org/10.1111/j.1744-9987.2012.01129.x.
Julius U, Siegert G, Kostka H, Schatz U, Hohenstein B. Effects of different lipoprotein apheresis methods on serum protein levels. Atheroscler Suppl. 2015a;18:95–102. https://doi.org/10.1016/j.atherosclerosissup.2015.02.018.
Julius U, Milton M, Stoellner D, Rader D, Gordon B, Polk D, et al. Effects of lipoprotein apheresis on PCSK9 levels. Atheroscler Suppl. 2015b;18:180–6. https://doi.org/10.1016/j.atherosclerosissup.2015.02.028.
Julius U, Tselmin S, Schatz U, Fischer S, Bornstein SR. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. Clin Res Cardiol Suppl. 2019;14(Suppl 1):45–50. https://doi.org/10.1007/s11789-019-00099-z.
Julius U, Kuss S, Tselmin S, Schatz U, Bornstein SR. Why some patients undergoing lipoprotein apheresis therapy develop new cardiovascular events? J Cardiovasc Dev Dis. 2020;7(3):30025. https://doi.org/10.3390/jcdd7030025.
Kamstrup PR. Lipoprotein(a) and cardiovascular disease. Clin Chem. 2021;67(1):154–66. https://doi.org/10.1093/clinchem/hvaa247.
Kassenärztliche Bundesvereinigung. Qualitätsbericht—Ausgabe 2014—Berichtsjahr 2013. Special edition. 2014. www.kbv.de.
Kassenärztliche Bundesvereinigung. Qualitätsbericht—Ausgabe 2015—Berichtsjahr 2014. Special edition. 2015. www.kbv.de.
Kassenärztliche Bundesvereinigung. Qualitätsbericht—Ausgabe 2016—Berichtsjahr 2015. Special edition. 2016. www.kbv.de.
Kassenärztliche Bundesvereinigung. Qualitätsbericht—Ausgabe 2017—Berichtsjahr 2016. Special edition. 2017. www.kbv.de.
Kassenärztliche Bundesvereinigung. Qualitätsbericht—Ausgabe 2018—Berichtsjahr 2017. Special edition. 2018. www.kbv.de.
Kassenärztliche Bundesvereinigung. Qualitätsbericht—Ausgabe 2019—Berichtsjahr 2018. Special edition. 2019. www.kbv.de.
Kassenärztliche Bundesvereinigung. Qualitätsbericht—Ausgabe 2020—Berichtsjahr 2019. Special edition. 2020. www.kbv.de.
Kassenärztliche Bundesvereinigung. Qualitätsbericht—Ausgabe 2021—Berichtsjahr 2020. Special edition. 2021. www.kbv.de.
Khan TZ, Hsu LY, Arai AE, Rhodes S, Pottle A, Wage R, et al. Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial. Eur Heart J. 2017;38(20):1561–9. https://doi.org/10.1093/eurheartj/ehx178.
Klingel R, Heigl F, Schettler V, Roeseler E, Grutzmacher P, Hohenstein B, et al. Lipoprotein(a)—marker for cardiovascular risk and target for lipoprotein apheresis. Atheroscler Suppl. 2019;40:17–22. https://doi.org/10.1016/j.atherosclerosissup.2019.08.037.
Koren MJ, Moriarty PM, Baum SJ, Neutel J, Hernandez-Illas M, Weintraub HS, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med. 2022;28(1):96–103. https://doi.org/10.1038/s41591-021-01634-w.
Korneva VA, Kuznetsova TY, Julius U. Modern approaches to lower lipoprotein(a) concentrations and consequences for cardiovascular diseases. Biomedicine. 2021;9(9):1271. https://doi.org/10.3390/biomedicines9091271.
Kronenberg F. Lipoprotein(a). Handb Exp Pharmacol. 2022;270:201–32. https://doi.org/10.1007/164_2021_504.
Kroon AA, van’t Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis. 2000;152(2):519–26. https://doi.org/10.1016/s0021-9150(00)00371-3.
Lamina C, Kronenberg F, for the Lp(a)-GWAS-Consortium. Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a Mendelian randomization analysis. JAMA Cardiol. 2019;4(6):575–9. https://doi.org/10.1001/jamacardio.2019.1041.
Langsted A, Nordestgaard BG. Lipoprotein(a) as part of the diagnosis of clinical familial hypercholesterolemia. Curr Atheroscler Rep. 2022;24(4):289–96. https://doi.org/10.1007/s11883-022-01002-0.
Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation. 2013;128(24):2567–76. https://doi.org/10.1161/CIRCULATIONAHA.113.002432.
Ma L, Waldmann E, Ooi EMM, Chan DC, Barrett HPR, Watts GF, et al. Lipoprotein(a) and low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease. Eur J Clin Investig. 2019;49(2):e13053. https://doi.org/10.1111/eci.13053.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;41:111–88. https://doi.org/10.1093/eurheartj/ehz455.
Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study. Arterioscler Thromb Vasc Biol. 2020;40(1):255–66. https://doi.org/10.1161/ATVBAHA.119.312951.
Makino H, Koezuka R, Tamanaha T, Ogura M, Matsuki K, Hosoda K, et al. Familial hypercholesterolemia and lipoprotein apheresis. J Atheroscler Thromb. 2019;26(8):679–87. https://doi.org/10.5551/jat.RV17033.
Mickiewicz A, Marlega J, Kuchta A, Bachorski W, Cwiklinska A, Raczak G, et al. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia(a): indications for lipoprotein apheresis in Poland. J Clin Apher. 2021;36(3):370–8. https://doi.org/10.1002/jca.21872.
Moriarty PM, Gray JV, Gorby LK. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease. J Clin Lipidol. 2019;13(6):894–900. https://doi.org/10.1016/j.jacl.2019.09.010.
Nave AH, von Eckardstein A. Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism? Clin Res Cardiol Suppl. 2019;14(Suppl 1):28–32. https://doi.org/10.1007/s11789-019-00101-8.
Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–53. https://doi.org/10.1093/eurheartj/ehq386.
O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483–92. https://doi.org/10.1161/CIRCULATIONAHA.118.037184.
Parish S, Hopewell JC, Hill MR, Marcovina S, Valdes-Marquez E, Haynes R, et al. Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study. Circ Genomic Precis Med. 2018;11(2):e001696. https://doi.org/10.1161/CIRCGEN.117.001696.
Pokrovsky SN, Afanasieva OI, Safarova MS, Balakhonova TV, Matchin YG, Adamova IYU, et al. Specific Lp(a) apheresis: a tool to prove lipoprotein(a) atherogenicity. Atheroscler Suppl. 2017;30:166–73. https://doi.org/10.1016/j.atherosclerosissup.2017.05.004.
Pokrovsky SN, Afanasieva OI, Ezhov MV. Therapeutic apheresis for management of Lp(a) hyperlipoproteinemia. Curr Atheroscler Rep. 2020;22(11):68. https://doi.org/10.1007/s11883-020-00886-0.
Poller WC, Berger A, Dreger H, Morgera S, Enke-Melzer K. Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study. Atheroscler Suppl. 2017;30:174–9. https://doi.org/10.1016/j.atherosclerosissup.2017.05.007.
Pouwer MG, Pieterman EJ, Worms N, Keijzer N, Jukema JW, Gromada J, et al. Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice. J Lipid Res. 2020;61(3):365–75. https://doi.org/10.1194/jlr.RA119000419.
Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48–60. https://doi.org/10.1161/ATV.0000000000000147.
Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, et al. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and Apo(a) characterization. Arterioscler Thromb Vasc Biol. 2016;36(9):2019–27. https://doi.org/10.1161/ATVBAHA.116.307983.
Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med. 2020;383(24):2307–19. https://doi.org/10.1056/NEJMoa2031049.
Ruscica M, Watts GF, Sirtori CR. PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies. Eur J Prev Cardiol. 2019;26(9):998–1000. https://doi.org/10.1177/2047487319833504.
Safarova MS, Ezhov MV, Afanasieva OI, Matchin YG, Atanesyan RV, Adamova IY, et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl. 2013;14(1):93–9. https://doi.org/10.1016/j.atherosclerosissup.2012.10.015.
Schatz U, Tselmin S, Muller G, Julius U, Hohenstein B, Fischer S, et al. Most significant reduction of cardiovascular events in patients undergoing lipoprotein apheresis due to raised Lp(a) levels—a multicenter observational study. Atheroscler Suppl. 2017;30:246–52. https://doi.org/10.1016/j.atherosclerosissup.2017.05.047.
Schettler V, Roeseler E, Thode C, Gruetzmacher P, Klingel R, Julius U. Differenzierung der Indikation zur Lipoproteinapherese bei erhöhtem Lp(a) durch unterschiedliche Messmethoden. Cardiovasc. 2015;15:41–3.
Schettler V, Bernhardt W, van Buuren F, Gruetzmacher P, Heigl F, Hohenstein B, et al. The German lipoprotein apheresis registry (GLAR)—almost 5 years on. Clin Res Cardiol Suppl. 2020;12(1):44–9.
Stefanutti C, Morozzi C, Di GS. Italian multicenter study on low-density lipoprotein apheresis working group 2009 survey. Ther Apher Dial. 2013;17(2):169–78. https://doi.org/10.1111/j.1744-9987.2012.01142.x.
Stefanutti C, Pisciotta L, Favari E, Di Giacomo S, Vacondio F, Zenti MG, et al. Lipoprotein(a) concentration, genetic variants, apo(a) isoform size, and cellular cholesterol efflux in patients with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresis: an Italian case-control multicenter study on Lp(a). J Clin Lipidol. 2020;14(4):487–97.e1. https://doi.org/10.1016/j.jacl.2020.05.002.
Stiekema LCA, Prange KHM, Hoogeveen RM, Verweij SL, Kroon J, Schnitzler JG, et al. Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). Eur Heart J. 2020;41(24):2262–71. https://doi.org/10.1093/eurheartj/ehaa171.
Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020;41(44):4245–55. https://doi.org/10.1093/eurheartj/ehaa649.
Thompson GR. The scientific basis and future of lipoprotein apheresis. Ther Apher Dial. 2022;26(1):32–6. https://doi.org/10.1111/1744-9987.13716.
Thompson G, Parhofer KG. Current role of lipoprotein apheresis. Curr Atheroscler Rep. 2019;21(7):26. https://doi.org/10.1007/s11883-019-0787-5.
Tmoyan NA, Ezhov MV, Afanasieva OI, Klesareva EA, Afanasieva MI, Balakhonova TV, et al. Association of lipoprotein(a) with ischemic stroke and stenotic carotid atherosclerosis. Zh Nevrol Psikhiatr Im S Korsakova. 2020;120(3. Vyp. 2):42–8. https://doi.org/10.17116/jnevro202012003242.
Trenkwalder E, Gruber A, Konig P, Dieplinger H, Kronenberg F. Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease. Kidney Int. 1997;52(6):1685–92. https://doi.org/10.1038/ki.1997.503.
Tselmin S, Muller G, Schatz U, Julius U, Bornstein SR, Hohenstein B. Kinetics of lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia. Atheroscler Suppl. 2017;30:209–16. https://doi.org/10.1016/j.atherosclerosissup.2017.05.033.
Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692–711. https://doi.org/10.1016/j.jacc.2016.11.042.
Tsimikas S. Potential causality and emerging medical therapies for lipoprotein(a) and its associated oxidized phospholipids in calcific aortic valve stenosis. Circ Res. 2019;124(3):405–15. https://doi.org/10.1161/CIRCRESAHA.118.313864.
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244–55. https://doi.org/10.1056/NEJMoa1905239.
von Dryander M, Fischer S, Passauer J, Muller G, Bornstein SR, Julius U. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern. Atheroscler Suppl. 2013;14(1):39–44. https://doi.org/10.1016/j.atherosclerosissup.2012.10.005.
Waldmann E, Parhofer KG. Lipoprotein apheresis to treat elevated lipoprotein(a). J Lipid Res. 2016;57(10):1751–7. https://doi.org/10.1194/jlr.R056549.
Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182–93. https://doi.org/10.1016/j.jacc.2020.12.058.
Yeang C, Witztum JL, Tsimikas S. ‘LDL-C’ = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol. 2015;26(3):169–78.
Yeang C, Hung MY, Byun YS, Clopton P, Yang X, Witztum JL, et al. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). J Clin Lipidol. 2016;10(3):594–603. https://doi.org/10.1016/j.jacl.2016.01.005.
Yeang C, Witztum JL, Tsimikas S. Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. J Lipid Res. 2021;62:100053. https://doi.org/10.1016/j.jlr.2021.100053.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Julius, U., Tselmin, S. (2023). Lipoprotein Apheresis for Reduction of Lipoprotein(a). In: Kostner, K., Kostner, G.M., Toth, P.P. (eds) Lipoprotein(a). Contemporary Cardiology. Humana, Cham. https://doi.org/10.1007/978-3-031-24575-6_23
Download citation
DOI: https://doi.org/10.1007/978-3-031-24575-6_23
Published:
Publisher Name: Humana, Cham
Print ISBN: 978-3-031-24574-9
Online ISBN: 978-3-031-24575-6
eBook Packages: MedicineMedicine (R0)